XOMA Corporation (XOMA)

[beambe]

Image courtesy Novartis Oncology$-$-$-$

In September 2015, XOMA licensed the global development and commercialization rights to its TGFß antibody program to Novartis. XOMA received $37.0 million upfront payment and is eligible to receive up to $480.0 million if all development, regulatory, and commercial milestones are met. In addition, XOMA is eligible to receive royalties on product sales that range from the mid-single digits to the low double digits


HCD122

We also have a product partnered with Novartis in our pipeline: HCD122, a monoclonal antibody to CD40.

HCD122
Image courtesy Novartis Oncology

http://www.xoma.com/content/pipeline/novartis-partnered.htm